{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-016833","form_type":"8-K","ticker":"HCA","cik":"0000860730","company_name":"HCA Healthcare, Inc.","filed_at":"2023-01-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.294944+00:00","generated_at":"2026-06-20T07:35:17.745694+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"HCA Healthcare Q4 net income $2.08B ($7.28 EPS); revenue $15.5B; new $3B buyback","bullets":["Q4 revenue $15.50B (+2.9% YoY); net income $2.08B ($7.28 diluted EPS) incl $1.33B facility-sale gains.","Adjusted EBITDA $3.18B vs $3.15B YoY; same-facility admissions +2.9%, ER visits +11.4%.","FY2022 revenue $60.23B, net income $5.64B ($19.15 EPS); adjusted EBITDA $12.07B.","Board authorized new $3B share repurchase program; declared quarterly dividend of $0.60/sh payable Mar 31.","2023 guidance: revenue $61.5-63.5B, EPS $16.40-17.60, capex ~$4.3B."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-016833","json":"https://secwatch.observer/filing/0001193125-23-016833.json","markdown":"https://secwatch.observer/filing/0001193125-23-016833.md","text":"https://secwatch.observer/filing/0001193125-23-016833.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/860730/000119312523016833/0001193125-23-016833-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/860730/000119312523016833/d268135d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T07:35:17.745694+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6d0289fc14ee88ff9289c3615ce5839ac8cde4d6","claim":"HCA Healthcare, Inc. reported fourth quarter ended December 31, 2022 results: revenue $15.497 billion, net income $2.081 billion, EPS $7.28 per diluted share. Guidance initiated.","evidence_excerpt":"results for the fourth quarter ended December 31, 2022. Key fourth quarter metrics (all percentage changes compare 4Q 2022 to 4Q 2021 unless otherwise noted): ● Revenues totaled $15.497 billion ● Net income attributable to HCA Healthcare, Inc. totaled $2.081 billion, or $7.28 per diluted share ● Adjusted EBITDA totaled $3.179 billion ● Cash flows from operating","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/860730/000119312523016833/0001193125-23-016833-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$15.497 billion"},{"label":"Net income","value":"$2.081 billion"},{"label":"EPS","value":"$7.28 per diluted share"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"927a4b8244d3f6f1c9938503ebcdca80df103313","claim":"HCA Healthcare, Inc. reported year ended December 31, 2022 results: revenue $60.233 billion, net income $5.643 billion, EPS $19.15 per diluted share. Guidance initiated.","evidence_excerpt":"Revenues for the year ended December 31, 2022 totaled $60.233 billion, compared to $58.752 billion in the same period of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/860730/000119312523016833/0001193125-23-016833-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2022"},{"label":"Revenue","value":"$60.233 billion"},{"label":"Net income","value":"$5.643 billion"},{"label":"EPS","value":"$19.15 per diluted share"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}